118569-21-4

Basic information

• Product Name: Zileuton (sodiuM)
• Synonyms: Zileuton (sodiuM)
• CAS NO: 118569-21-4
• Molecular Formula: C11H12N2NaO2S *
• Molecular Weight: 259.27995
• Mol File: 118569-21-4.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Solubility: Soluble in DMSO
• CAS DataBase Reference: Zileuton (sodiuM)(CAS DataBase Reference)
• NIST Chemistry Reference: Zileuton (sodiuM)(118569-21-4)
• EPA Substance Registry System: Zileuton (sodiuM)(118569-21-4)

Safety Data

• Hazardous Substances Data: 118569-21-4(Hazardous Substances Data)

Usage

Biological Activity

zileuton sodium is an inhibitor of 5-lipoxygenase, and thus inhibits leukotrienes(ltb4, ltc4, ltd4 and lte4) formation with an ic50 value of 0.5μm [1].zileuton sodium has been reported to concentration-dependently inhibit the 5-lipoxygenase activity with an ic50 value of 0.5μm in rbl-1cell lysate. in addition, zileuton sodium has been found to be a potent inhibitor of ltb formation with an ic50 value of 0.6μm. furthermore, stimulated with a23187, zileuton sodium has shown a dose-dependent reduction in ltb4 and 5-hete generation in rat leukocyte with ic50 values of 0.38μm and 0.31μm, respectively. about 40-fold higher concentrations of zileuton sodium also reduced the production of pge2 with a ic50 of 16μm [1].

references

[1] carter gw1, young pr, albert dh, bouska j, dyer r, bell rl, summers jb, brooks dw. 5-lipoxygenase inhibitory activity of zileuton. j pharmacol exp ther. 1991 mar; 256(3):929-37.

Upstream product

• 1070-89-9 sodium hexamethyldisilazane 
• 142606-21-1 zileuton 

Relevant articles and documents

Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds

Compounds of the formula: STR1 wherein R1 is (1) hydrogen, (2) C1 to C4 alkyl, (3) C2 to C4 alkenyl, or (4) NR2 R3, wherein R2 and R3 are independently selected from (1) hydrogen, (2) C1 to C4 alkyl and (3) hydroxyl, but R2 and R3 are not simultaneously hydroxyl; wherein X is oxygen, sulfur, SO2, or NR4, wherein R4 is (1) hydrogen, (2) C1 to C6 alkyl, (3) C1 to C6 alkoyl, (4) aroyl, or (5) alkylsulfonyl; A is selected from C1 to C6 alkylene and C2 to C6 alkenylene; n is 1-5; Y is selected independently at each occurrence from (1) hydrogen, (2) halogen, (3) hydroxy, (4) cyano, (5) halosubstituted alkyl, (6) C1 to C12 alkyl, (7) C2 to C12 alkenyl, (8) C1 to C12 alkoxy, (9) C3 to C8 cycloalkyl, (10) C1 -C8 thioalkyl, (11) aryl, (12) aryloxy, (13) aroyl, (14) C1 to C12 arylalkyl, (15) C2 to C12 arylalkenyl, (16) C1 to C12 arylalkoxy, (17) C1 to C12 arylthioalkoxy, and substituted derivatives of (18) aryl, (19) aryloxy, (20) aroyl, (21) C1 to C12 arylalkyl, (22) C2 to C12 arylalkenyl, (23) C1 to C12 arylalkoxy, or (24) C1 to C12 arylthioalkoxy, wherein substituents are selected from halo, nitro, cyano, C1 to C12 alkyl, alkoxy, and halosubstituted alkyl; Z is oxygen or sulfur; and M is hydrogen, a pharmaceutically acceptable cation, aroyl, or C1 to C12 alkoyl, are potent inhibitors of 5- and/or 12-lipoxygenase enzymes. Also disclosed are lipoxygenase inhibiting compositions and a method for inhibiting lipoxygenase activity.